Like a laser, COVID-19 traced the shocking contours of inequality in America's health system—demonstrating that science and health equity have always been inseparable.
As a Latina, I feel deeply impacted when I see reports of hate crimes against ethnic and racial minorities in the news. The recent string of news reports highlighting police brutality and the victimization of black people has caused a great deal of pain in my heart, prompting me to reflect on my own experiences.
A reading list is a glimpse into the soul of a community. A reading list is also a reflection of a time. And a projection of visions of the future.
In 1971, when the National Cancer Act was signed, Walter Lawrence, Jr., was one of the surgeons eager for a push forward, driven by rigorous science reviewed and funded by the federal government.
Tecentriq (atezolizumab) received FDA approval in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Tecartus (brexucabtagene autoleucel), a cell-based gene therapy, received FDA approval for treatment of adult patients diagnosed with mantle cell lymphoma who have not responded to or who have relapsed following other kinds of treatment.
Keytruda has received two sBLA acceptances from FDA for the treatment of triple negative breast cancer:
The hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate, received Breakthrough Designation from FDA for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required.
FDA has cleared an investigational new drug application for CT-0508, an anti-human epidermal growth factor receptor 2-targeted chimeric antigen receptor macrophage.
BDTX-189 has received Fast Track Designation from FDA for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 mutation or an epidermal growth factor receptor or HER2 Exon 20 insertion mutation who have progressed following prior treatment and who have no satisfactory treatment options.
